Ovarian Cancer Diagnostics Market (2035): Imaging, Biomarker Testing & Molecular Diagnostics Growth in United States Expansion

DataM Intelligence has released a new research report titled "Ovarian Cancer Diagnostics Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the competitive landscape. It also highlights major growth drivers shaping the ovarian cancer diagnostics market, including advancements in imaging, biomarker testing, molecular diagnostics, and genetic screening.

Download Sample Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/ovarian-cancer-diagnostics-market?sindhuri

Recent Key Developments - United States & North America
✅ September 2026: Cleo Diagnostics received the first commercially manufactured batch of its eight-biomarker pre-surgical ovarian cancer test, produced by Bio-Techne, and began analytical validation. The company is using three independently manufactured batches to assess precision, reproducibility, manufacturing consistency, and analytical robustness ahead of a planned FDA 510(k) submission.

✅ September 2026: A U.S.-linked study published in Gynecologic Oncology demonstrated an AI-based ovarian cancer risk-prediction model built from 150,907 screening events. The model was externally validated and is being positioned as a potential component of multimodal early-detection strategies rather than as a standalone diagnostic.

✅ September 2026: Research from the University of Minnesota and collaborators advanced the use of routine liquid-based Pap-test samples as a source of ovarian cancer protein biomarkers. The work builds on a mass-spectrometry approach designed to identify ovarian cancer signals from cervical samples, potentially creating a diagnostic pathway that uses specimens already collected for cervical screening.

Recent Key Developments - Japan & Asia-Pacific
✅ July 2026: Findings from Japan's MONSTAR-SCREEN-3 program reported initial results using a whole-genome-sequencing-based circulating tumor DNA assay for molecular residual disease detection in ovarian cancer. The study involved the National Cancer Center Hospital East and multiple Japanese cancer centers, reflecting growing use of ctDNA for molecular monitoring beyond conventional serum markers.

✅ September 2026: Researchers in South Korea published clinical validation of a thioredoxin 1 (Trx1) plus CA125 biomarker strategy for ovarian cancer. The work evaluated the combination as a potential approach for distinguishing early-stage ovarian cancer, adding Trx1 to the established CA125 marker rather than relying on CA125 alone.

✅ September 2026: Chinese researchers reported a multimodal liquid-biopsy approach combining cfDNA fragmentomics with CA125 and HE4 for differentiating malignant from benign ovarian tumors. In an external validation cohort, the integrated model reached an AUC of 0.964 and substantially improved specificity compared with the cfDNA-only approach, highlighting the shift toward combining genomic and conventional serum signals.

Recent Key Developments - Diagnostic Technology & Product Innovation
✅ July 2026: A prospective study introduced a three-metabolite urine signature for non-invasive identification of high-risk ovarian cancer, adding urine metabolomics to the expanding range of blood-based and tissue-based diagnostic approaches under investigation.

✅ September 2026: New research explored serum peptidomic signatures for detecting asymptomatic ovarian cancer, using a multicenter prospective study to evaluate peptide patterns as an early-detection signal. The approach reflects increasing interest in protein and peptide fingerprints that can complement conventional CA125 testing.

✅ September 2026: Research into small extracellular-vesicle protein signatures combined with O-RADS ultrasound showed particular potential for the difficult O-RADS 3/4 group of adnexal masses. The integrated approach achieved 86.1% diagnostic accuracy in this intermediate-risk subgroup, compared with 69.6% for CA125 alone.

List of Key Players 2026:
F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Abbott, Myriad Genetic Laboratories, Foundation Medicine Inc. and Laboratory Corporation of America Holdings

Company Evaluation
Leading healthcare and diagnostic companies such as Roche, Siemens Healthineers, Quest Diagnostics and Thermo Fisher Scientific are strengthening their presence in the ovarian cancer diagnostics market through advanced imaging, biomarker testing, molecular diagnostics and laboratory testing solutions.

Innovative companies such as Myriad Genetics and Foundation Medicine are advancing precision diagnostics through genomic testing, biomarker analysis and personalized cancer profiling, while improvements in early detection technologies continue to support market development.

Growth Forecast Projected 2026:
The Global ovarian cancer diagnostics market was valued at US$1.85 billion in 2025 and is projected to reach US$3.55 billion by 2035, expanding at a CAGR of 6.7% during 2026-2035 supported by increasing demand for early cancer detection, advances in diagnostic technologies, rising adoption of biomarker testing and growing investments in cancer diagnostics. Asia Pacific is identified as the fastest-growing region, while North America holds the largest market share.

Get a Customized Industry Report:
https://www.datamintelligence.com/customize/ovarian-cancer-diagnostics-market?sindhuri

M&A / Strategic Activity
Recent strategic partnerships, clinical collaborations, and commercialization moves shaping the Ovarian Cancer Diagnostics Market:

Cleo Diagnostics - Bio-Techne strategic manufacturing and platform collaboration
Cleo Diagnostics selected Bio-Techne's EllaTM automated immunoassay platform to run its multi-biomarker ovarian cancer blood test. The collaboration has moved beyond technology selection into commercial manufacturing: Bio-Techne began producing clinical-grade test kits, while Cleo entered analytical validation using three independently manufactured batches. Cleo reported receipt of its first commercial production batch in September 2026, with FDA 510(k) submission targeted for H1 2027.

Cleo Diagnostics - Asuragen clinical-validation partnership
Cleo has extended its relationship with Bio-Techne through Asuragen, a Bio-Techne brand and CLIA-certified U.S. laboratory, to support pivotal clinical validation of its pre-surgical ovarian cancer test. The program is designed to generate clinical-performance data from more than 1,300 samples, including sensitivity, specificity, positive predictive value, and negative predictive value.

Quest Diagnostics - MD Anderson multi-cancer risk-stratification collaboration
In June 2025, Quest Diagnostics and MD Anderson Cancer Center announced a collaboration to develop and validate a laboratory-developed blood test based on circulating protein biomarkers associated with elevated risk across several cancers, including ovarian cancer. The project moves ovarian diagnostics beyond single-marker testing toward a broader blood-based risk-stratification model.

Quest Diagnostics - City of Hope ctDNA research deployment
In April 2026, Quest Diagnostics and City of Hope launched a multi-year research program using Haystack MRD® ctDNA testing in patients with breast, colorectal, ovarian, and prostate cancers. Fourteen City of Hope sites are participating, with the program expected to involve approximately 500 patients and thousands of longitudinal measurements. This places ovarian cancer within an expanding MRD-testing workflow focused on monitoring disease at the molecular level.

Myriad Genetics - Expansion of the MyChoice CDx companion-diagnostic role
The FDA updated Myriad's MyChoice® CDx in March 2026 from a complementary diagnostic to a companion diagnostic for Zejula in ovarian cancer. The updated indication covers deleterious or suspected deleterious BRCA1/2 mutations and/or a positive genomic instability score, reinforcing HRD testing as a treatment-selection component rather than simply a research biomarker.

New Product/Diagnostic Launches & Deployments
Recent diagnostic products, regulatory expansions, and clinical deployments in ovarian cancer:

Agilent Technologies - PD-L1 IHC 22C3 pharmDx for ovarian cancer
In February 2026, the FDA approved PD-L1 IHC 22C3 pharmDx as a companion diagnostic for identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and who may be eligible for KEYTRUDA® treatment. Agilent subsequently received EU certification for the same ovarian cancer indication in July 2026.

Labcorp - U.S. clinical availability of PD-L1 ovarian cancer testing
In April 2026, Labcorp announced nationwide availability of Agilent's FDA-approved PD-L1 IHC 22C3 pharmDx for ovarian cancer. The move expands access to companion-diagnostic testing through a national laboratory network rather than limiting testing to individual oncology centers.

Illumina - TruSight Oncology Comprehensive HRD (DRAGEN)
Illumina's CE-marked TruSight Oncology Comprehensive HRD (DRAGEN) combines BRCA1/2 variant detection with genomic instability scoring from FFPE ovarian tumor tissue. The assay uses Illumina NGS and the Myriad Genetics GIS algorithm, with validation across 615 unique ovarian samples and a reported 95.3% overall agreement with the clinical trial assay in its olaparib bridging study.

Cleo Diagnostics - Eight-biomarker pre-surgical blood test
Cleo expanded its proprietary pre-surgical ovarian cancer biomarker panel from five to eight biomarkers during its commercial-development program. The test is designed to distinguish benign from malignant adnexal masses using a blood sample and is being developed for a pre-surgical triage setting rather than population-wide screening.

Roche - FOLR1 testing integrated into ovarian cancer treatment selection
Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay remains an important tissue-based companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal cancers. The assay identifies tumors meeting the ≥75% viable tumor-cell membrane-staining threshold used to determine eligibility for FOLR1-targeted therapy. Roche also featured FOLR1 testing in its 2026 European pathology program, reflecting continued attention to biomarker-driven ovarian cancer workflows.

R&D & Technological Advancements
Multiomics and cfDNA-based characterization of adnexal masses
Research using Illumina technology is moving ovarian diagnostics beyond conventional protein markers. A 2026 USC study combined cell-free DNA, proteomics, and spatial transcriptomics to investigate differences between malignant and benign adnexal masses. The work is aimed at identifying molecular signals that can improve characterization before surgery.

OvaPrint and methylation-based liquid biopsy
At AGBT 2026, researchers presented OvaPrint, a cell-free DNA methylation-based liquid-biopsy approach designed to assess ovarian cancer risk in women presenting with adnexal masses. The reported work achieved 96% specificity for the evaluated application and also explored methylation signals that may help identify non-high-grade-serous ovarian cancers.

Glycovariant analysis of CA-125
NCI-supported research is examining whether the molecular structure of CA-125 can provide information that conventional CA-125 concentration misses. A 2025 PLCO project is specifically investigating cancer-associated glycosylation patterns of MUC16/CA-125, including sialylation, fucosylation, and related glycan changes, as potential early-detection signals.

Multi-marker algorithms for early detection
The NCI-funded MD Anderson EDRN program is continuing clinical validation of multi-marker approaches combining CA-125 with additional biomarkers, including TP53, CTAG1, and IL-8 autoantibody-related signals. The program is designed to evaluate whether combining biomarkers can improve early-stage detection and recurrence monitoring compared with relying on CA-125 alone.

AI-assisted imaging for ovarian mass classification
A 2026 study involving AIIMS New Delhi and C-DAC Pune evaluated machine-learning models for differentiating ovarian cancer from benign ovarian masses using radiological variables. Random Forest and Support Vector Machine models achieved reported accuracies of 85.87% and 83.05%, respectively, although the researchers emphasized that larger prospective studies are still required before clinical implementation.

HRD testing moving toward localized testing workflows in India
At the 2025 ASCO meeting, researchers reported results from an Indian HRD-testing implementation program in which 567 healthcare professionals ordered 3,315 HRD tests. Seventy-two percent of samples produced conclusive results, while the local laboratory-developed test showed an 82% conclusive rate and a 22-working-day turnaround compared with 23 days for the kit-based approach.

Unlock & Gain Complete 360° Market Visibility:
https://www.datamintelligence.com/buy-now-page?report=ovarian-cancer-diagnostics-market?sindhuri

Segments Covered in the Global Ovarian Cancer Diagnostics Market:
By Diagnosis Type
The market is segmented into imaging, blood test, biopsy, and others. Imaging dominates the market due to its widespread use in detecting ovarian abnormalities, identifying tumors, and assessing disease progression through ultrasound, CT, MRI, and other diagnostic techniques. Blood tests are witnessing strong growth due to increasing use of tumor markers such as CA-125 for supporting ovarian cancer detection and monitoring. Biopsy remains essential for confirming malignancy and determining tumor characteristics, while other diagnostic methods serve complementary roles in specialized clinical settings.

By Cancer Type
The market is divided into epithelial tumor, stromal cell tumor, germ cell tumor, and others. Epithelial tumors dominate the market due to their high prevalence among ovarian cancer cases and the resulting demand for early detection and diagnostic evaluation. Stromal cell tumors represent a specialized segment requiring targeted diagnostic approaches, while germ cell tumors are increasingly supported by improved diagnostic techniques, particularly for younger patients. Other cancer types account for less common ovarian malignancies and specialized diagnostic requirements.

By End-User
The market is segmented into hospitals, cancer diagnostic centers, and others. Hospitals dominate the market due to the availability of comprehensive diagnostic infrastructure, specialist oncology teams, advanced imaging technologies, and laboratory services. Cancer diagnostic centers are witnessing steady growth driven by increasing demand for specialized cancer screening, diagnostic testing, and early detection services. Other end-users include specialized clinics and healthcare facilities that provide ovarian cancer diagnostic services.

By Region
North America - 34% Share
North America leads the market due to advanced healthcare infrastructure, high adoption of diagnostic technologies, increasing awareness of ovarian cancer screening and early detection, and strong availability of specialized oncology services across the United States and Canada.

Europe - 28% Share
Europe is driven by well-established healthcare systems, growing emphasis on early cancer detection, increasing access to advanced imaging and laboratory diagnostics, and continued investment in oncology care across countries such as Germany, France, the UK, and Italy.

Asia-Pacific - 30% Share
Asia-Pacific is expanding rapidly due to the growing burden of cancer, improving healthcare infrastructure, increasing access to advanced diagnostic technologies, and rising awareness of early ovarian cancer detection in countries such as China, Japan, India, and South Korea.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.